News & Updates

New drug applications approved by US FDA as of 16-31 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Parallel testing of interleukin (IL)-10 to IL-6 and MYD88 demonstrates the highest diagnostic performance among strategies evaluated for primary vitreoretinal lymphoma (PVRL), suggests a study.

Treatment with gildeuretinol acetate capsules helps slow the growth of retinal atrophic lesions in individuals with Stargardt disease, according to the phase II TEASE-1 trial.

Problematic digital media use is associated with increased risks of mental health issues, self-harm or suicidal ideation, sleep problems, and substance use among adolescents. Physical-health outcomes, including obesity, myopia, and cardiometabolic risk, have been reported across all ages spanning childhood to adolescence. Thirteen global experts called for immediate public health action worldwide in a series of three papers published in The Lancet.

In patients with autoimmune disorders, ocular inflammation appears to increase the risk of anti-adalimumab antibodies (AAA) development, suggests a study.

A five-infusion course of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), over 12 weeks results in improved diplopia, proptosis, and disease activity and is well tolerated in patients with active thyroid eye disease (TED), as shown in the phase III THRIVE study. Moreover, the therapeutic effect persists through week 52.

Patients prescribed NSAIDs appear protected against the development of age-related macular degeneration (AMD) compared with nonusers, suggests a study.